Pfizer (PFE) Soars 3.27% on 10% Revenue Jump

Pfizer's stock surged 3.27% in pre-market trading on August 5, 2025, driven by strong financial performance and positive outlook.

Pfizer reported robust second-quarter 2025 results, with revenues jumping 10% year-over-year to $14.7 billion. This impressive performance led the company to raise its 2025 earnings per share (EPS) guidance to a range of $2.90 to $3.10. The strong quarterly results reflect Pfizer's focused execution and strategic initiatives, which have positioned the company for continued growth.

Pfizer's positive outlook and strong financial performance have bolstered investor confidence, contributing to the stock's pre-market surge. The company's ability to exceed revenue expectations and raise EPS guidance underscores its resilience and strategic acumen in a competitive pharmaceutical landscape.